Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Indication (Pain Management, Oncology, CNS Condition, Diabetes, Obesity), By Region, And Segment Forecasts, 2023 - 2030

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Phase
1.1.2. Study Design
1.1.3. Indication
1.1.4. Regional Scope
1.1.5. Estimates and Forecast Timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.4. Information or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity Flow Analysis (Model 1)
1.6.1.1. Approach 1: Commodity Flow Approach
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1: Understanding the Market Dynamics
1.9.2. Objective 2: Understanding the Market Estimates and Forecasts
1.9.3. Objective 3: Understanding the Attributes such as Strategy Framework, Competitor Categorization
1.9.4. Objective 4: Understanding the Key Product and Application Scopes to Conclude on the Market Size
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Product Pipeline Analysis, by Stage
3.2.1. Therapeutics in Development
3.2.2. Vaccines in Development
3.3. Fast-Track of Clinical Trials
3.3.1. FDA Initiative - CTPA
3.3.2. U.K. Initiative - ACCORD
3.3.3. ASIA Pacific Initiative - DCGI
3.3.4. University of Pittsburgh School of Medicine - UPMC
3.4. Solidarity Clinical Trials
3.4.1. Participation in Solidarity Trials
3.4.2. Solidarity Clinical Trial for Vaccines
3.5. Virtual Clinical Trials
3.5.1. In-Home Clinical Services
3.6. COVID-19 Impact on Clinical Trials
3.6.1. Companies with Phase 1 Trial Disruption
3.6.2. Companies with Phase 2 Trial Disruption
3.6.3. Companies with Phase 3 Trial Disruption
3.7. Market Dynamics
3.7.1. Market Driver Analysis
3.7.1.1. Increasing Research and Development Promoting Outsourcing
3.7.1.2. Adoption of New Technology in Clinical Research
3.7.1.3. Increasing Prevalence of Chronic Disease
3.7.1.4. Globalization of Clinical Trials
3.7.2. Market Restraint Analysis
3.7.2.1. Stringent Regulatory Policies for Patient Enrollment
3.7.2.2. Lack of Skilled Workforce in Clinical Research
3.7.3. Industry Challenges
3.7.3.1. Rising Cost of Clinical Trial
3.8. Clinical Trials: Market Analysis Tools
3.8.1. Industry Analysis - Porter’s
3.8.1.1. Supplier Power
3.8.1.2. Buyer Power
3.8.1.3. Substitution Threat
3.8.1.4. Threat from New Entrant
3.8.1.5. Competitive Rivalry
3.8.2. PESTEL Analysis
3.8.2.1. Political Landscape
3.8.2.2. Environmental Landscape
3.8.2.3. Social Landscape
3.8.2.4. Technology Landscape
3.8.2.5. Legal Landscape
3.8.3. Major Deals & Strategic Alliances Analysis
Chapter 4. Clinical Trials Market: Segment Analysis, by Phase, 2017 - 2030 (USD Million)
4.1. Definitions & Scope
4.2. Phase Market Share Analysis, 2021 & 2030
4.3. Segment Dashboard
4.4. Global Clinical Trials Market, by Phase, 2017 to 2030
4.5. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the Following
4.5.1. Phase I
4.5.2. Phase II
4.5.3. Phase III
4.5.4. Phase IV
Chapter 5. Clinical Trials Market: Segment Analysis, By Study Design, 2017 - 2030 (USD Million)
5.1. Definitions & Scope
5.2. Study Design Market Share Analysis, 2021 & 2030
5.3. Segment Dashboard
5.4. Global Clinical Trials Market, By Study Design, 2017 to 2030
5.5. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
5.5.1. Interventional
5.5.2. Observational
5.5.3. Expanded Access
Chapter 6. Clinical Trials Market: Segment Analysis, By Indication, 2017 - 2030 (USD Million)
6.1. Definitions & Scope
6.2. Indication Market Share Analysis, 2021 & 2030
6.3. Segment Dashboard
6.4. Global Clinical Trials Market, By Indication, 2017 to 2030
6.5. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
6.5.1. Autoimmune/Inflammation
6.5.2. Pain Management
6.5.3. Oncology
6.5.4. CNS Condition
6.5.5. Diabetes
6.5.6. Obesity
6.5.7. Cardiovascular
6.5.8. Others
Chapter 7. Clinical Trials Market: Segment Analysis, Indication by Study Design, 2017 - 2030 (USD Million)
7.1. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
7.1.1. Autoimmune/inflammation
7.1.1.1. Interventional
7.1.1.2. Observational
7.1.1.3. Expanded Access
7.1.2. Pain Management
7.1.2.1. Interventional
7.1.2.2. Observational
7.1.2.3. Expanded Access
7.1.3. Oncology
7.1.3.1. Interventional
7.1.3.2. Observational
7.1.3.3. Expanded Access
7.1.4. CNS condition
7.1.4.1. Interventional
7.1.4.2. Observational
7.1.4.3. Expanded Access
7.1.5. Diabetes
7.1.5.1. Interventional
7.1.5.2. Observational
7.1.5.3. Expanded Access
7.1.6. Obesity
7.1.6.1. Interventional
7.1.6.2. Observational
7.1.6.3. Expanded Access
7.1.7. Cardiovascular
7.1.7.1. Interventional
7.1.7.2. Observational
7.1.7.3. Expanded Access
7.1.8. Others
7.1.8.1. Interventional
7.1.8.2. Observational
7.1.8.3. Expanded Access
Chapter 8. Clinical Trials Market: Segment Analysis, by Sponsor, 2017 - 2030 (USD Million)
8.1. Definitions & Scope
8.2. Study Design Market Share Analysis, 2021 & 2030
8.3. Segment Dashboard
8.4. Global Clinical Trials Market, By Sponsor, 2017 to 2030
8.5. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
8.5.1. Pharmaceutical & Biopharmaceutical Companies
8.5.2. Medical Device Companies
8.5.3. Others
Chapter 9. Clinical Trials Market: Segment Analysis, by Service Type, 2017 - 2030 (USD Million)
9.1. Definitions & Scope
9.2. Study Design Market Share Analysis, 2021 & 2030
9.3. Segment Dashboard
9.4. Global Clinical Trials Market, By Service Type, 2017 to 2030
9.5. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
9.5.1. Protocol Designing
9.5.2. Site Identification
9.5.3. Patient Recruitment
9.5.4.实验室服务
9.5.5. Bioanalytical Testing Services
9.5.6. Clinical Trial Data Management Services
9.5.7. Others
Chapter 10. Clinical Trials Market: Regional Market Analysis, by Region, 2017 - 2030 (USD Million)
10.1. Definitions & Scope
10.2. Regional Market Share Analysis, 2021 & 2030
10.3. Regional Market Dashboard
10.4. Regional Market Share, 2020
10.5. Market Size, & Forecasts, and Trend Analysis, 2017 to 2030:
10.6. North America
10.6.1. Market Estimates and Forecast, by Country, 2017 - 2030 (USD Million)
10.6.2. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.6.3. Market Estimates and Forecast, by Study design, 2017 - 2030 (USD Million)
10.6.4. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.6.5. U.S.
10.6.5.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.6.5.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.6.5.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.6.5.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.6.6. Canada
10.6.6.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.6.6.2. Market Estimates and Forecast, by study design, 2017 - 2030 (USD Million)
10.6.6.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.6.6.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.7. Europe
10.7.1.市场估计和预测,国家,2017 - 2030 (USD Million)
10.7.2. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.7.3. Market Estimates and Forecast, by study design, 2017 - 2030 (USD Million)
10.7.4. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.7.5. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.7.6. Germany
10.7.6.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.7.6.2. Market Estimates and Forecast, by study design, 2017 - 2030 (USD Million)
10.7.6.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.7.6.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.7.7. U.K.
10.7.7.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.7.7.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.7.7.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.7.7.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.7.8. France
10.7.8.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.7.8.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.7.8.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.7.8.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.7.9. Italy
10.7.9.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.7.9.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.7.9.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.7.9.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.7.10. Spain
10.7.10.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.7.10.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.7.10.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.7.10.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.7.11. Denmark
10.7.11.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.7.11.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.7.11.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.7.11.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.7.12. Sweden
10.7.12.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.7.12.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.7.12.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.7.12.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.7.13. Norway
10.7.13.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.7.13.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.7.13.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.7.13.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.8. Asia Pacific
10.8.1. Market Estimates and Forecast, by country, 2017 - 2030 (USD Million)
10.8.2. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.8.3. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.8.4. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.8.5. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.8.6. China
10.8.6.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.8.6.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.8.6.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.8.6.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.8.7. Japan
10.8.7.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.8.7.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.8.7.3.市场估计和预测,籼稻tion, 2017 - 2030 (USD Million)
10.8.7.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.8.8. India
10.8.8.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.8.8.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.8.8.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.8.8.4.市场估计和预测,通过Sponsor, 2017 - 2030 (USD Million)
10.8.10. Australia
10.8.9.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.8.9.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.8.9.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.8.9.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.8.10. South Korea
10.8.10.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.8.10.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.8.10.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.8.10.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.8.11. Thailand
10.8.11.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.8.11.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.8.11.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.8.11.4.市场估计和预测,通过Sponsor, 2017 - 2030 (USD Million)
10.9. Latin America
10.9.1. Market Estimates and Forecast, by country, 2017 - 2030 (USD Million)
10.9.2. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.9.3. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.9.4. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.9.5. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.9.6. Brazil
10.9.6.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.9.6.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.9.6.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.9.6.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.9.7. Mexico
10.9.7.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.9.7.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.9.7.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.9.7.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.9.8. Argentina
10.9.8.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.9.8.2.估计和预测,市场研究Design, 2017 - 2030 (USD Million)
10.9.8.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.9.8.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.9.9. Colombia
10.9.9.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.9.9.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.9.9.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.9.9.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.10. Middle East and Africa
10.10.1. Market Estimates and Forecast, by country, 2017 - 2030 (USD Million)
10.10.2. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.10.3. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.10.4. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.10.5. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.10.6. South Africa
10.10.6.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.10.6.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.10.6.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.10.6.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.10.7. Saudi Arabia
10.10.7.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.10.7.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.10.7.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.10.7.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.10.8. UAE
10.10.8.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.10.8.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.10.8.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.10.8.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
10.10.9. Kuwait
10.10.9.1. Market Estimates and Forecast, by Phase, 2017 - 2030 (USD Million)
10.10.9.2. Market Estimates and Forecast, by Study Design, 2017 - 2030 (USD Million)
10.10.9.3. Market Estimates and Forecast, by Indication, 2017 - 2030 (USD Million)
10.10.9.4. Market Estimates and Forecast, by Sponsor, 2017 - 2030 (USD Million)
Chapter 11. Clinical Trials Market - Competitive Analysis
11.1. Key Companies Profiled
11.1.1. IQVIA
11.1.1.1. Company Overview
11.1.1.2. Financial Performance
11.1.1.3. Product Benchmarking
11.1.1.4. Strategic Initiatives
11.1.2. PAREXEL International Corporation
11.1.2.1. Company Overview
11.1.2.2. Financial Performance
11.1.2.3.产品Benchmarking
11.1.2.4. Strategic Initiatives
11.1.3. Pharmaceutical Product Development, LLC
11.1.3.1. Company Overview
11.1.3.2.金融Performance
11.1.3.3. Product Benchmarking
11.1.3.4. Strategic Initiatives
11.1.4. Charles River Laboratory
11.1.4.1. Company Overview
11.1.4.2. Financial Performance
11.1.4.3. Product Benchmarking
11.1.4.4. Strategic Initiatives
11.1.5. ICON Plc
11.1.5.1. Company Overview
11.1.5.2. Financial Performance
11.1.5.3. Product Benchmarking
11.1.5.4. Strategic Initiatives
11.1.6. Wuxi AppTec Inc
11.1.6.1. Company Overview
11.1.6.2. Financial Performance
11.1.6.3. Product Benchmarking
11.1.6.4. Strategic Initiatives
11.1.7. SGS SA
11.1.7.1. Company Overview
11.1.7.2. Financial Performance
11.1.7.3. Product Benchmarking
11.1.7.4. Strategic Initiatives
11.1.8. Syneos Health
11.1.8.1. Company Overview
11.1.8.2. Financial Performance
11.1.8.3. Product Benchmarking
11.1.8.4. Strategic Initiatives
11.1.9. Chiltern International Ltd
11.1.9.1. Company Overview
11.1.9.2. Financial Performance
11.1.9.3. Product Benchmarking
11.1.9.4. Strategic Initiatives
11.1.10. Eli Lilly and Company
11.1.10.1. Company Overview
11.1.10.2. Financial Performance
11.1.10.3. Product Benchmarking
11.1.10.4. Strategic Initiatives
11.1.11. Novo Nordisk A/S
11.1.11.1. Company Overview
11.1.11.2. Financial Performance
11.1.11.3. Product Benchmarking
11.1.11.4. Strategic Initiatives
11.1.12. Pfizer
11.1.12.1. Company Overview
11.1.12.2. Financial Performance
11.1.12.3. Product Benchmarking
11.1.12.4. Strategic Initiatives
11.1.13. Clinipace
11.1.13.1. Company Overview
11.1.13.2. Financial Performance
11.1.13.3. Product Benchmarking
11.1.13.4. Strategic Initiatives
Chapter 12. KOL Commentary

List of Tables

Table. 1 Table 1 List of secondary sources
Table. 2 List of abbreviations
Table. 3 Therapeutics in development
Table. 4 Vaccines in development
Table. 5 Vaccines in development for COVID-19
Table. 6 Impact of COVID-19 on new patients entering trials
Table. 7 Impact of COVID-19 on other therapeutic areas
Table. 8 Strategic collaborations by key players
Table. 9 Interventional studies
Table. 10 Blood cancer clinical trials
Table. 11 Medicines in development for neurological disorders, 2018
Table. 12 Number of Alzheimer’s disease clinical trials, by phase
Table. 13 Top 10 therapy areas by phase

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Volume price analysis
Fig. 9 Clinical trials market snapshot (2021)
Fig. 10 Clinical trials market segmentation
Fig. 11 Clinical trials market: Strategy framework
Fig. 12 Parent market outlook
Fig. 13 Related/ancillary market outlook
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Virtual clinical trials
Fig. 16 Companies with affected trials, by size
Fig. 17 Affected trials, by study phase
Fig. 18 Market driver relevance analysis (Current & future impact)
Fig. 19 Market restraint relevance analysis (Current & future impact)
Fig. 20 Porter’s five forces analysis
Fig. 21 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 22 Clinical trials market phase outlook: Segment dashboard
Fig. 23 Clinical trials market: Phase movement analysis
Fig. 24 Phase I market, 2017 - 2030 (USD Million)
Fig. 25 Phase II market, 2017 - 2030 (USD Million)
Fig. 26 Phase III market, 2017 - 2030 (USD Million)
Fig. 27 Phase IV market, 2017 - 2030 (USD Million)
Fig. 28 Clinical trials market: Study design outlook: Segment dashboard
Fig. 29 Clinical trials market: Study design movement analysis
Fig. 30 Interventional studies market, 2017 - 2030 (USD Million)
Fig. 31 Observational studies market, 2017 - 2030 (USD Million)
Fig. 32 Expanded access studies market, 2017 - 2030 (USD Million)
Fig. 33 Clinical trials market indication outlook: Segment dashboard
Fig. 34 Clinical trials market: Indication movement analysis
Fig. 35 Autoimmune clinical trial by phase, 2021 (%)
Fig. 36 Autoimmune/inflammation market, 2017 - 2030 (USD Million)
Fig. 37 Rheumatoid arthritis clinical trial by phase (%)
Fig. 38 Rheumatoid arthritis market, 2017 - 2030 (USD Million)
Fig. 39 Multiple sclerosis clinical trial by phase (%)
Fig. 40 Multiple sclerosis market, 2017 - 2030 (USD Million)
Fig. 41 Osteoarthritis clinical trials by phase (%)
Fig. 42 Osteoarthritis market, 2017 - 2030 (USD Million)
Fig. 43 Irritable Bowel Syndrome (IBS) market, 2017 - 2030 (USD Million)
Fig. 44 Others market, 2017 - 2030 (USD Million)
Fig. 45 Pain management market, 2017 - 2030 (USD Million)
Fig. 46 Chronic pain clinical trial by phase (%)
Fig. 47 Chronic pain market, 2017 - 2030 (USD Million)
Fig. 48 Acute pain clinical trial by phase (%)
Fig. 49 Acute pain market, 2017 - 2030 (USD Million)
Fig. 50 Oncology market, 2017 - 2030 (USD Million)
Fig. 51 Blood cancer market, 2017 - 2030 (USD Million)
Fig. 52 Solid tumors market, 2017 - 2030 (USD Million)
Fig. 53 Others market, 2017 - 2030 (USD Million)
Fig. 54 CNS conditions market, 2017 - 2030 (USD Million)
Fig. 55 Epilepsy market, 2017 - 2030 (USD Million)
Fig. 56 Parkinson's disease (PD) market, 2017 - 2030 (USD Million)
Fig. 57 Huntington's disease market, 2017 - 2030 (USD Million)
Fig. 58 Stroke market, 2017 - 2030 (USD Million)
Fig. 59 Traumatic Brain Injury (TBI) market, 2017 - 2030 (USD Million)
Fig. 60 Amyotrophic lateral sclerosis (ALS) market, 2017 - 2030 (USD Million)
Fig. 61 Muscle regeneration market, 2017 - 2030 (USD Million)
Fig. 62 Others market, 2017 - 2030 (USD Million)
Fig. 63 Diabetes market, 2017 - 2030 (USD Million)
Fig. 64 64 Obesity clinical trial by phase (%)
Fig. 65 Obesity market, 2017 - 2030 (USD Million)
Fig. 66 Cardiovascular market, 2017 - 2030 (USD Million)
Fig. 67 Others indications market, 2017 - 2030 (USD Million)
Fig. 68 Autoimmune/inflammation interventional studies market, 2017 - 2030 (USD Million)
Fig. 69 Autoimmune/inflammation observational studies market, 2017 - 2030 (USD Million)
Fig. 70 Autoimmune/inflammation expanded access market, 2017 - 2030 (USD Million)
Fig. 71 Pain management interventional studies market, 2017 - 2030 (USD Million)
Fig. 72 Pain management observational studies market, 2017 - 2030 (USD Million)
Fig. 73 Pain management expanded access market, 2017 - 2030 (USD Million)
Fig. 74 Oncology interventional studies market, 2017 - 2030 (USD Million)
Fig. 75 Oncology observational studies market, 2017 - 2030 (USD Million)
Fig. 76 Oncology expanded access market, 2017 - 2030 (USD Million)
Fig. 77 CNS conditions interventional studies market, 2017 - 2030 (USD Million)
Fig. 78 CNS conditions observational studies market, 2017 - 2030 (USD Million)
Fig. 79 CNS conditions expanded access market, 2017 - 2030 (USD Million)
Fig. 80 Diabetes interventional studies market, 2017 - 2030 (USD Million)
Fig. 81 Diabetes observational studies market, 2017 - 2030 (USD Million)
Fig. 82 Diabetes expanded access market, 2017 - 2030 (USD Million)
Fig. 83 Obesity interventional studies market, 2017 - 2030 (USD Million)
Fig. 84 Obesity observational studies market, 2017 - 2030 (USD Million)
Fig. 85 Obesity expanded access market, 2017 - 2030 (USD Million)
Fig. 86 Cardiovascular interventional studies market, 2017 - 2030 (USD Million)
Fig. 87 Cardiovascular observational studies market, 2017 - 2030 (USD Million)
Fig. 88 Cardiovascular expanded access market, 2017 - 2030 (USD Million)
Fig. 89 Others interventional studies market, 2017 - 2030 (USD Million)
Fig. 90 Others observational studies market, 2017 - 2030 (USD Million)
Fig. 91 Others expanded access market, 2017 - 2030 (USD Million)
Fig. 92 Clinical trials market: Sponsor outlook: Segment dashboard
Fig. 93 Clinical trials market: Sponsor movement analysis
Fig. 94 Pharmaceutical & biopharmaceutical companies market, 2017 - 2030 (USD Million)
Fig. 95 Medical device companies market, 2017 - 2030 (USD Million)
Fig. 96 Others market, 2017 - 2030 (USD Million)
Fig. 97 Clinical trials market: Service Type outlook: Segment dashboard
Fig. 98 Clinical trials market: Service Type movement analysis
Fig. 99 Protocol Designing market, 2017 - 2030 (USD Million)
Fig. 100 Site Identification market, 2017 - 2030 (USD Million)
Fig. 101 Patient Recruitment market, 2017 - 2030 (USD Million)
Fig. 102 Laboratory Services market, 2017 - 2030 (USD Million)
Fig. 103 Bioanalytical Testing Services market, 2017 - 2030 (USD Million)
Fig. 104 Clinical Trial Data Management Services market, 2017 - 2030 (USD Million)
Fig. 105 Others market, 2017 - 2030 (USD Million)
Fig. 106 Regional market: Key takeaways
Fig. 107 Regional market share, 2021
Fig. 108 Regional outlook, 2021 & 2030
Fig. 109 North America market, 2017 - 2030 (USD Million)
Fig. 110 U.S. market, 2017 - 2030 (USD Million)
Fig. 111 Canada market, 2017 - 2030 (USD Million)
Fig. 112 Europe market, 2017 - 2030 (USD Million)
Fig. 113 Fig. 1 U.K. market, 2017 - 2030 (USD Million)
Fig. 114 Germany market, 2017 - 2030 (USD Million)
Fig. 115 France market, 2017 - 2030 (USD Million)
Fig. 116 Italy market, 2017 - 2030 (USD Million)
Fig. 117 Spain market, 2017 - 2030 (USD Million)
Fig. 118 Denmark market, 2018 - 2030 (USD Million)
Fig. 119 Sweden market, 2018 - 2030 (USD Million)
Fig. 120 Norway market, 2018 - 2030 (USD Million)
Fig. 121 Asia Pacific market, 2017 - 2030 (USD Million)
Fig. 122 India market, 2017 - 2030 (USD Million)
Fig. 123 Japan market, 2017 - 2030 (USD Million)
Fig. 124 China market, 2017 - 2030 (USD Million)
Fig. 125 Thailand market, 2017 - 2030 (USD Million)
Fig. 126 South Korea market, 2017 - 2030 (USD Million)
Fig. 127 Australia market, 2018 - 2030 (USD Million)
Fig. 128 Latin America market, 2017 - 2030 (USD Million)
Fig. 129 Brazil market, 2017 - 2030 (USD Million)
Fig. 130 Mexico market, 2017 - 2030 (USD Million)
Fig. 131 Argentina market, 2017 - 2030 (USD Million)
Fig. 132 Colombia market, 2017 - 2030 (USD Million)
Fig. 133 MEA market, 2017 - 2030 (USD Million)
Fig. 134 South Africa market, 2017 - 2030 (USD Million)
Fig. 135 Saudi Arabia market, 2017 - 2030 (USD Million)
Fig. 136 UAE market, 2017 - 2030 (USD Million)
Fig. 137 Kuwait market, 2017 - 2030 (USD Million)